Skip to main content
Figure 2 | BMC Medicine

Figure 2

From: Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial

Figure 2

Safety and toxicity. Cumulative timing of adverse events between the arms (A). Stool consistency (Bristol Stool Form Scale) and frequency in the 24 hours preceding clinical review (B,C). Hepatic enzymes, aspartate aminotransferase (AST), alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT), for all participants in the study (D). Change in hepatic enzymes from baseline to day 7 (E). Creatinine and hemoglobin for all participants (F,G). Differences between arms at baseline are highlighted if P <0.1, upper limit of normal (alongside lower limit for creatinine) illustrated where appropriate.

Back to article page